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LETTERS
Gene-Environment Interactions and Depression
To the Editor: In their meta-analysis, Dr Risch and col-
leagues1 concluded that the study of gene-environment in-
teraction in mental disorders should await the identifica-
tion of “robust marginal gene associations.” We believe that
this conclusion extends well beyond the data, and an alter-
nate explanation of their findings suggests other courses of
action. The absence of replicable findings across studies that
assessed both direct genotype-depression associations and
gene-environment interactions may be explained by mismea-
surement and undermeasurement of relevant environmen-
tal contexts.
Two compelling strands of evidence support this hypoth-
esis. First, there is a sharp contrast in the consistency of suc-
cess in studies that have sought genotype-phenotype asso-
ciations in animals and in humans. For example, animal
models of depression and anxiety disorders have consis-
tently demonstrated genotype-phenotype associations.2 By
contrast, a recent genome-wide association study (GWAS)
of depression found no significant associations.3 One cen-
tral difference between these 2 research approaches lies in
control over potentially relevant environmental expo-
sures. These exposures are effectively randomized in ani-
mal models, but such control is absent from observational
human gene-hunting studies.
Second, outside the gene-environment literature re-
viewed by Risch et al,1 the evidence for environmental modi-
fication of genetic effects on human behavior is robust and
increasing. The heritability of many phenotypes is modi-
fied by environmental factors such as socioeconomic sta-
tus.4 Genotype-phenotype associations are also modified by
context familiarity in animal models2 and features of social
environments in human studies.5 Unmeasured aspects of en-
vironmental context could contribute to nonreplication of
gene-environment findings that at best limit the measure-
ment of environment to life events.
Rather than conducting less research on how genotype
and a range of environmental factors jointly produce men-
tal disorders, what is needed is more and better-quality re-
search. Unfortunately, to date GWAS of mental disorders
have exclusively tested for genetic main effects, and gene-
environment interaction studies have focused on candi-
date genes and individual-level measures of environmental
exposures. Genome-wide association studies of mental dis-
orders may produce more robust findings if populations were
sampled conditional on exposure to a range of plausible en-
vironmental risk factors. Gene-environment interaction stud-
ies would benefit from moving away from focus on single
candidate genes and toward considering multiple levels of
environmental exposures.
Studies that integrate state-of-the-science methods of mea-
surement of both genetic and environmental factors will
provide a more comprehensive test of the role of gene-
environment interaction in mental disorders than a meta-
analysis of a single gene–environmental risk factor disor-
der association.
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To the Editor: We have some concerns with the meta-
analysis by Dr Risch and colleagues,1 which examined the
role of 5-HTTLPR in moderating the relationship between
stress and depression. We agree with the authors that blan-
ket acceptance of a robust and universal interaction be-
tween 5-HTTLPR and stress is unwarranted, and it is pre-
mature to translate this into clinical and forensic settings.
However, the authors concluded that the original finding
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was not confirmed, despite numerous independent posi-
tive reports in the literature. Other conclusions should be
considered.
First, the studies included in the meta-analysis had no-
table heterogeneity in measurement of both environment
(life events) and outcome (depression). Numerous sources
of error measurement, such as recall bias, vaguely worded
questions or anchors, and rater bias, can reduce the preci-
sion of measurement. Approximately 73% of the partici-
pants in this meta-analysis came from cross-sectional/
retrospective studies, often using brief assessments, phone
assessments, or both. Examples of studies that can mea-
sure environmental stressors with high precision include pro-
spective studies of depression after quantifiable events (eg,
job loss, pregnancy, hip fracture, heart disease, cytokine
exposure),2-4 and such studies were excluded from this meta-
analysis. A reasonable conclusion is that the authors showed
that the likelihood of finding a gene-environment interac-
tion is influenced by study design and that more effort needs
to be put into prospective high-precision measurement of
both environment and outcome.
Second, many factors may alter or mitigate the gene-
environment interaction. These include age, the timing of
stressor (recent stresses vs remote life events), ethnicity, an-
tidepressant medication use, and social supports. It is dif-
ficult to interpret the null finding of a meta-analysis that com-
bined all such factors.
Many but not all prospective studies have replicated in-
creased depression incidence in individuals under stress who
have the S/S genotype. Rather than conclude that there is no
evidence for this, continued prospective research with a greater
emphasis on precision and confounding variables is needed.
There are preclinical data from animal models, neuroimag-
ing, physiology, and epigenetics,5 and evidence exists for po-
tential interactions with other genes and other polymor-
phisms in the serotonin transporter. This accumulating body
of evidence may be useful in interpreting past association stud-
ies (assessing the mixture of positive and null results) and
carefully designing future prospective studies.
Francis E. Lotrich, MD, PhD
lotrichfe@upmc.edu
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To the Editor: In their meta-analysis, Dr Risch and col-
leagues1 reported on gene-environment interactions in de-
pressive disorders, focusing on the interaction between the
serotonin transporter promoter polymorphism and life
events. They stated that “the samples, study designs, mea-
sures, and analyses were highly divergent across studies,
thereby limiting the comparability of the studies and their
evidence regarding replication.” However, the authors did
not address 2 other problems arising from the methodol-
ogy of their meta-analysis.
First, although some original studies used a nondi-
chotomized dimensional outcome and thus reported
additive interaction effects, the study by Risch and col-
leagues1 applied a multiplicative or log-additive model to
estimate the interaction effects for a dichotomized out-
come in all studies. Thus, studies that previously
reported significant gene-environment interaction effects
with a dimensional outcome measure in an additive
model, such as the study by Grabe et al,2 lost this effect in
a multiplicative model with an arbitrary dichotomization
of the outcome. Moreover, for a dichotomized outcome
the absence of an interaction in the multiplicative model
implies the presence of an interaction in the additive
model when both environmental and genetic factors have
effects.3 Therefore, it may have been misleading to apply
the same multiplicative model to all studies included in
the meta-analysis.
Second, even for a dichotomized outcome an additive mea-
sure of an interaction effect is available (relative risk excess
due to interaction).3,4 For a dichotomous outcome, the ad-
ditive measure, not the multiplicative measure, allows a causal
interpretation of the results.3 Recently proposed versions of
the additive measure allow differentiating detailed types of
gene-environment interactions on a dichotomous out-
come (or outcomes that can be recoded as dichotomous
outcome).3 Among the interaction types, synergism is of great
interest because it suggests joint work of the genetic and
the environment factors on the outcome. The synergistic ac-
tion can be identified by applying the corresponding modi-
fied measure for an additive interaction effect on a dichoto-
mized outcome.3
We recommend the use of additive models for future gene-
environment interaction studies. The use of dichotomized
outcomes will additionally allow for the calculation of the
relative risk excess due to interaction based on 42 tables,
which should constitute the fundamental core of the sta-
tistical analysis of gene-environment interactions.3-5
Christian Schwahn, PhD
schwahn@uni-greifswald.de
Institute of Epidemiology and Social Medicine
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To the Editor: Dr Risch and colleagues1 concluded that the
results of a study2 showing that the serotonin transporter gene
(5-HTTLPR) genotype moderates the effect of stressful life
events on the risk of depression could not be replicated in a
meta-analysis of 14 studies. The authors pointed out the im-
portance of replication studies before new findings are trans-
lated into clinical and health practices. We believe that it is
also important to note that editorial practices of scientific jour-
nals may contribute to the lack of attention received by stud-
ies that fail to replicate original findings.
The original study2 was published in 2003 in Science, a
prominent journal with a very high impact factor that year.3
In the year following its publication, it was cited 110 times
in sources indexed in the Web of Science citation report.4
In 2005, the first study that failed to replicate the original
finding5 in a sample of 1091 participants was published in
Psychological Medicine, a specialized journal with a rela-
tively low impact factor. That study was cited 24 times in
the following year.
We believe that unless editors actively encourage the sub-
mission of null findings, replication studies, and contradic-
tory results alike, the premature uncritical adoption of new
findings will continue to influence the way resources are
allocated in research and clinical practice settings. Studies
that do not replicate an important finding and that meet high
methodological standards should be considered for publi-
cation by influential journals at the same level as the re-
spective original reports. This will encourage researchers to
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In Reply: We agree with Drs Koenen and Galea and Drs
Lotrich and Lenze regarding the importance of consistent
environmental measures in studies of gene-environment in-
teraction. However, it is also important to acknowledge the
myriad ways an environmental exposure is defined and po-
tentially adjusted to identify an interaction effect in gene-
environment interaction studies when assessing statistical
significance. For example, Lotrich and Lenze are critical of
our meta-analysis for excluding studies with single hetero-
geneous life stressors such as job loss, pregnancy, hip frac-
ture, or heart disease. However, exposure to a single life event
was not significantly associated with depression in the origi-
nal study of Caspi et al,1 in which (as shown in Figure 1 of
that article) an interaction with the 5-HTTLPR genotype oc-
curred only among persons with 3 or more stressful life
events.
Lotrich and Lenze also fault our analysis for failing to ex-
amine the effects of study design (prospective vs retrospec-
tive) and potential factors that may confound the associa-
tion between a stressful life event and depression, such as
ethnicity, age, antidepressant medication, and social sup-
ports. Our analysis found a consistent effect of stressful life
events on depression (10 of 14 studies) irrespective of the
method for assessing li fe events, and the gene-
environment interaction results did not differ by sample size,
prospective vs retrospective design, or control for age and
ethnicity. The gene-environment interaction effect was no
stronger for those studies with vs those without a main effect
of stressful life events.
There also appears to be confusion regarding heteroge-
neity of results among studies and between what consti-
tutes “positive reports” vs “replications.” Although we noted
significant heterogeneity in the main effect of stressful life
events, we found no between-study heterogeneity in the gene-
LETTERS
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environment interaction results. While we agree that there
have been positive reports, we disagree that these have been
replications. Many studies that had reported positive find-
ings were not replications, mostly because the interaction
effects occurred in a direction opposite to that first re-
ported1 or the key study variables had not been assessed in
a comparable way. For example, Drs Schwann and Grabe
suggest that our interpretation of their study results2 dif-
fered from theirs because of our use of a multiplicative rather
than additive model of interaction and dichotomization of
their continuous depression scale. Our gene-environment
interaction results were in the same direction as their pub-
lished findings,2 even though we used the same multipli-
cative model as in the study by Caspi et al.1 Furthermore,
as Schwann and Grabe point out, the model of interaction
is only important when “both environmental and genetic
factors have effects.” While our meta-analysis yielded strong
support for the environmental effect of life events on de-
pression, the most consistent finding across all studies in-
cluded in our analysis was the lack of effect of 5-HTTLPR
on depression. In addition, we also reanalyzed the data sub-
mitted to us for meta-analysis by Grabe et al using their con-
tinuous depression scale and found no evidence of interac-
tion, using an additive or any other model.
Cited evidence from animal and human experimental stud-
ies of stress reactivity has no bearing on the results of our
meta-analysis. While such data might provide an increased
prior belief that an association should exist, only data from
subsequent observational studies in humans can serve to as-
sess the original study associations.
Finally, we agree with Dr Rieckmann and colleagues, who
highlight the importance of publication bias and negative
reports in adjudging the full spectrum of evidence for rep-
lication.
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Postherpetic Neuralgia in Herpes Zoster
To the Editor: In his Clinical Crossroads article discussing
herpes zoster, Dr Whitley1 stated that our Cochrane re-
view2 reported no benefit of valacyclovir for prevention of
postherpetic neuralgia (PHN) at 4 or 6 months after rash
onset. However, this is not accurate; our review did not in-
clude any trials of valacyclovir.
In addition, Whitley stated that “[p]revention of PHN is
a major concern because antiviral drugs alone do not reli-
ably prevent this complication.” Although the results of ran-
domized controlled trials and meta-analyses showing that
antiviral drugs reduce the risk of developing PHN can be
challenged, the overall findings support the use of antiviral
therapy for herpes zoster to reduce the duration or inci-
dence of prolonged pain.3 Cut points used to define PHN
have ranged from 1 to 6 months after onset of zoster2,4; using
a definition of PHN as pain present for more than 30 days
after the onset of rash caused by herpes zoster, our review2
indicates that antiviral drugs significantly reduce the inci-
dence of PHN. We also note that recent evidence-based rec-
ommendations for the management of patients with her-
pes zoster recommend using antiviral therapy to decrease
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In Reply: Dr Zhou and colleagues address several points re-
garding my Clinical Crossroads article. They are correct in
noting an inaccuracy in the article regarding their Coch-
rane review. The sentence in question should have read, “A
Cochrane review of antiviral treatment for preventing PHN
reported no benefit of acyclovir for reducing the incidence
of PHN; there was insufficient evidence to determine the
efficacy of other antivirals.” A correction appears in this is-
sue of JAMA.
I stand by my statement that “[p]revention of PHN is a
major concern because antiviral drugs alone do not reli-
ably prevent this complication.” The US Food and Drug Ad-
ministration (FDA), using the definition of PHN cited by
Zhou et al, concluded that although treatment may de-
crease the median duration of pain (as a continuum), the
data from well-controlled clinical trials did not provide evi-
dence of reduction of PHN for any of the licensed drugs:
acyclovir,1 valacyclovir,2 or famciclovir.3 The FDA refused
to grant this indication based on its analyses and input from
advisory committees.
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